BNP Paribas Financial Markets Purchases 155,179 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

BNP Paribas Financial Markets boosted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYAFree Report) by 295.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 207,735 shares of the company’s stock after purchasing an additional 155,179 shares during the period. BNP Paribas Financial Markets owned about 0.32% of IDEAYA Biosciences worth $7,391,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in IDYA. Federated Hermes Inc. raised its stake in shares of IDEAYA Biosciences by 14.8% in the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock worth $138,185,000 after acquiring an additional 500,046 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of IDEAYA Biosciences during the 4th quarter worth approximately $12,328,000. Walleye Capital LLC acquired a new stake in shares of IDEAYA Biosciences during the 3rd quarter worth approximately $2,265,000. Boone Capital Management LLC grew its position in shares of IDEAYA Biosciences by 15.0% during the 3rd quarter. Boone Capital Management LLC now owns 570,682 shares of the company’s stock worth $15,397,000 after buying an additional 74,249 shares during the period. Finally, New York State Common Retirement Fund grew its position in shares of IDEAYA Biosciences by 98.6% during the 4th quarter. New York State Common Retirement Fund now owns 40,657 shares of the company’s stock worth $1,447,000 after buying an additional 20,185 shares during the period. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Down 2.5 %

NASDAQ:IDYA opened at $40.50 on Friday. The company has a market cap of $3.07 billion, a P/E ratio of -20.15 and a beta of 0.83. IDEAYA Biosciences, Inc. has a twelve month low of $20.84 and a twelve month high of $47.74. The business has a 50 day moving average price of $41.96 and a two-hundred day moving average price of $39.13.

IDEAYA Biosciences (NASDAQ:IDYAGet Free Report) last announced its earnings results on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. During the same quarter last year, the firm posted ($0.49) EPS. The firm’s quarterly revenue was down 100.0% on a year-over-year basis. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -2.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on IDYA shares. Wedbush reiterated an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, May 8th. BTIG Research started coverage on shares of IDEAYA Biosciences in a report on Friday, March 8th. They set a “buy” rating and a $55.00 price objective for the company. Citigroup boosted their price objective on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, March 21st. Capital One Financial restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Thursday, February 22nd. Finally, Leerink Partnrs restated an “outperform” rating on shares of IDEAYA Biosciences in a report on Friday, February 23rd. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $46.80.

Check Out Our Latest Analysis on IDEAYA Biosciences

Insider Activity

In related news, CEO Yujiro S. Hata sold 56,711 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares of the company’s stock, valued at $28,206,878.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Yujiro S. Hata sold 56,711 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the sale, the chief executive officer now owns 677,887 shares in the company, valued at approximately $28,206,878.07. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Yujiro S. Hata sold 34,433 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $41.81, for a total transaction of $1,439,643.73. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares of the company’s stock, valued at $28,342,455.47. The disclosure for this sale can be found here. 3.50% of the stock is owned by corporate insiders.

IDEAYA Biosciences Profile

(Free Report)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Featured Articles

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYAFree Report).

Institutional Ownership by Quarter for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.